0000000000624691

AUTHOR

Francesc Xavier Cos Claramunt

0000-0003-3943-479x

showing 3 related works from this author

Corrigendum to “Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance…

2020

medicine.medical_specialtyNutrition and DieteticsCardiovascular safetybusiness.industryEndocrinology Diabetes and MetabolismMEDLINEType 2 Diabetes MellitusPrimary caremedicine.diseaseClinical trialDiabetes mellitusInternal MedicineMedicineFamily PracticebusinessIntensive care medicinePrimary Care Diabetes
researchProduct

Manejo de la hiperglucemia con fármacos no insulínicos en pacientes adultos con diabetes tipo 2

2019

Resumen: El adecuado tratamiento de la diabetes mellitus tipo 2 (DM2) incluye la alimentación saludable y el ejercicio (150 min/semana) como pilares básicos. Para el tratamiento farmacológico, la metformina es el fármaco de elección inicial, salvo contraindicación o intolerancia; en caso de mal control, se dispone de 8 familias terapéuticas (6 orales y 2 inyectables) como posibles combinaciones. Se presenta un algoritmo y unas recomendaciones para el tratamiento de la DM2. En prevención secundaria cardiovascular se recomienda asociar un inhibidor del cotransportador sodio-glucosa tipo 2 (iSGLT2) o un agonista del receptor de glucagon-like peptide-1 (arGLP1) en pacientes con obesidad. En pre…

Agonistmedicine.medical_specialtymedicine.drug_class030204 cardiovascular system & hematologyOverweight:Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet::Diabetic Diet [Medical Subject Headings]GastroenterologyDiabetes tipo 2:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]03 medical and health sciences0302 clinical medicineFármacos antidiabéticos:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperglycemia [Medical Subject Headings]Internal medicineDiabetes mellitusmedicineGliclazide030212 general & internal medicineHiperglucemiaContraindicationlcsh:R5-920business.industryAntidiabetic drugs:Diseases::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus Type 2 [Medical Subject Headings]nutritional and metabolic diseases:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology Social::Life Style [Medical Subject Headings]Type 2 diabetesGeneral Medicinemedicine.diseaseSulfonylureaObesityHumanos:Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings]MetforminHyperglycemia:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents [Medical Subject Headings]medicine.symptomlcsh:Medicine (General)Family Practicebusinessmedicine.drug
researchProduct

Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care.

2019

Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes mellitus (T2DM). Furthermore, CKD confers a considerable increase in the risk of cardiovascular (CV) morbidity and mortality. In line with the need to improve knowledge in this field, this article aims to describe the renal endpoints used in the different cardiovascular outcome trials (CVOTs). The objective is to better know the renal variables used in the different CVOTs in order to optimize the implementation of advances in the prevention of progressive diabetic kidney disease in patients with T2DM in clinical practice.

medicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismDiseasePrimary careType 2 diabetesurologic and male genital diseasesGlobal HealthDiabetic nephropathy03 medical and health sciences0302 clinical medicineRisk FactorsDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsDiabetic Nephropathies030212 general & internal medicineIntensive care medicineNutrition and DieteticsPrimary Health Carebusiness.industryType 2 Diabetes Mellitusmedicine.diseaseClinical trialSurvival RateDiabetes Mellitus Type 2Cardiovascular DiseasesMorbidityFamily PracticebusinessKidney diseasePrimary care diabetes
researchProduct